Knight Therapeutics formaliza un acuerdo de licencia exclusivo con Supernus Pharmaceuticals para Qelbree® (viloxazina) in Canada

Posted on by

MONTREAL, 19 de diciembre, 2023 /PRNewswire/ — Knight Therapeutics Inc., (TSX: GUD) (“Knight”) una compañía de especialidades farmacéuticas panamericana (ex-EE. UU.), anunció hoy que ha formalizado un acuerdo de licencia exclusivo con Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN)…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.